Vistagen (VTGN) announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Cote will lead the evaluation of strategic opportunities to advance Vistagen’s pherine platform and cultivate prospective strategic partnerships. Cote previously served as fractional Chief Business Officer and strategic advisor to several biopharmaceutical clients and held senior roles at Mallinckrodt Pharmaceuticals, Sucampo Pharmaceuticals, and MedImmune. Vistagen also granted Cote an incentive option to purchase up to 150,000 shares of common stock.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges
- Vistagen Therapeutics Reports Progress in Clinical Trials
- Closing Bell Movers: Futures extend decline amid Middle East tension
- VistaGen Files Prospectus to Raise $175 Million
- Vistagen reports FY25 EPS ($1.67), two estimates ($1.74)